Treatment Details – 12.7 months
|Patients: This phase II study involved 102 patients with malignant pleural mesothelioma that were not candidates for curative surgery. The median patient age was 65, ranging from 38 to 79. Seventy-six were men and 26 were women.|
Treatment: All patients were treated with the chemotherapy drugs pemetrexed and carboplatin. They also were given supplements of folic acid and Vitamin B12.
Toxicity: Grade 4 toxicicites reported were anemia was reported in one patient, thrombocytopenia in 2, and neutropenia in 11 (2 of which were febrile). Grade 3-4 nausea/vomiting, fatigue, and diarrhea occurred in a few patients. The most common toxicity was nausea/vomiting.
Results: The medial survival time was 12.7 months. At a 14.2 month follow-up, 47 patients were still alive, 26 of whom did not have evidence of disease progression.
Correspondence: Giovanni Luca Ceresoli, M.D.